In advance of an FDA advisory committee meeting on Wednesday, agency reviewers note several issues concerning a Pfizer pill, the first oral biologic, for treating rheumatoid arthritis.
Ed Silverman, Forbes
Mon, 05/07/2012 - 2:39pm
In advance of an FDA advisory committee meeting on Wednesday, agency reviewers note several issues concerning a Pfizer pill, the first oral biologic, for treating rheumatoid arthritis.